StockData
Allogene Therapeutics, Inc. logo

Allogene Therapeutics, Inc. (ALLO) stock

ALLONasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 3/30
$0.70−0.05 (-6.48%)

Close on Nov 18, 2026Market cap $240.43MP/E –Yield 0.00%

Allogene Therapeutics free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Allogene Therapeutics's free cash flow for the twelve months ending Jun 30, 2026 was -$102.60M. For fiscal 2025 it was -$149.63M. The highest annual figure on record is -$47.89M in fiscal 2018.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$149.63M–
FY2024Dec 31, 2024-$200.99M–
FY2023Dec 31, 2023-$239.25M–
FY2022Dec 31, 2022-$225.71M–
FY2021Dec 31, 2021-$206.26M–
FY2020Dec 31, 2020-$181.05M–
FY2019Dec 31, 2019-$188.14M–
FY2018Dec 31, 2018-$47.89M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$32.15M–
Q1 FY2026Mar 31, 2026-$12.92M–
Q4 FY2025Dec 31, 2025-$27.60M–
Q3 FY2025Sep 30, 2025-$29.93M–
Q2 FY2025Jun 30, 2025-$39.07M–
Q1 FY2025Mar 31, 2025-$53.03M–
Q4 FY2024Dec 31, 2024-$36.96M–
Q3 FY2024Sep 30, 2024-$44.54M–
Q2 FY2024Jun 30, 2024-$63.59M–
Q1 FY2024Mar 31, 2024-$55.91M–
Q4 FY2023Dec 31, 2023-$53.89M–
Q3 FY2023Sep 30, 2023-$55.54M–
Q2 FY2023Jun 30, 2023-$62.15M–
Q1 FY2023Mar 31, 2023-$67.67M–
Q4 FY2022Dec 31, 2022-$63.79M–
Q3 FY2022Sep 30, 2022-$47.88M–
Q2 FY2022Jun 30, 2022-$43.91M–
Q1 FY2022Mar 31, 2022-$70.14M–
Q4 FY2021Dec 31, 2021-$46.17M–
Q3 FY2021Sep 30, 2021-$52.23M–
Q2 FY2021Jun 30, 2021-$52.07M–
Q1 FY2021Mar 31, 2021-$55.79M–
Q4 FY2020Dec 31, 2020-$27.38M–
Q3 FY2020Sep 30, 2020-$57.84M–
Q2 FY2020Jun 30, 2020-$42.78M–
Q1 FY2020Mar 31, 2020-$53.06M–
Q4 FY2019Dec 31, 2019-$64.38M–
Q3 FY2019Sep 30, 2019-$50.34M–
Q2 FY2019Jun 30, 2019-$32.75M–
Q1 FY2019Mar 31, 2019-$40.68M-813680.0%
Q4 FY2018Dec 31, 2018-$22.80M–
Q3 FY2018Sep 30, 2018-$18.51M–
Q2 FY2018Jun 30, 2018-$6.58M–
Q1 FY2018Mar 31, 2018$5.00K–

More Allogene Therapeutics figures

See a number that looks wrong?